EP3661514
Mavakamten til notkunar við meðhöndlun á ofvaxtarhjartavöðvakvilla
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.8.2018EP published:
17.9.2025EP application number:
18759209.2
EP translation filed:
26.11.2025Grant published:
15.12.2025EPO information:
European Patent Register
Max expiry date:
2.8.2038Expiry date:
2.8.2026
Title in English:
MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHYLanguage of the patent:
English
Timeline
Today
3.8.2018EP application
17.9.2025EP Publication
26.11.2025Translation submitted
15.12.2025Registration published
2.8.2026Expires
Owner
Name:
MyoKardia, Inc.Address:
1000 Sierra Point Parkway, Brisbane, CA 94005, US
Inventor
Name:
SEMIGRAN, Marc J.Address:
Brisbane, CA 94005, US
Name:
LEE, June H.Address:
Brisbane, CA 94005, US
Name:
LAMBING, JosephAddress:
Brisbane, CA 94005, US
Name:
GREEN, EricAddress:
Brisbane, CA 94005, US
Name:
EVANCHIK, MarcAddress:
Brisbane, CA 94005, US
Name:
CARLSON, TimothyAddress:
Belmont, CA 94002, US
Name:
ZHANG, DavidAddress:
San Carlos, CA 94070, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201762541591 PDate:
4.8.2017Country:
US
Number:
201762584537 PDate:
10.11.2017Country:
US
Number:
201862639922 PDate:
7.3.2018Country:
US
Number:
201862671585 PDate:
15.5.2018Country:
US
Classification
Categories:
A61K 31/513, A61P 9/04, A61P 9/10